Intra-Arterial Immunoselected CD34 Stem Cells for Acute Ischemic Stroke
Soma Banerjee, Paul Bentley, Mohammad Hamady, Stephen Marley, John Davis, Abdul Shlebak, Joanna Nicholls, Deborah A Williamson, Steen L Jensen, Myrtle Gordon, Nagy Habib, Jeremy Chataway
STEM CELLS Translational Medicine | ALPHAMED PRESS | Published : 2014
Treatment with CD34+ hematopoietic stem/progenitor cells has been shown to improve functional recovery in nonhuman models of ischemic stroke via promotion of angiogenesis and neurogenesis. We aimed to determine the safety and feasibility of treatment with CD34+ cells delivered intra-arterially in patients with acute ischemic stroke. This was the first study in human subjects. We performed a prospective, nonrandomized, open-label, phase I study of autologous, immunoselected CD34+ stem/progenitor cell therapy in patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score≥8). CD34+ cells were collected fro..View full abstract
This study was funded by Omnicyte Ltd. P.B. is funded by a Higher Education Funding Council for England Department of Health award. J.C. received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. The funding sources had no role in the study design, data collection, interpretation, or compilation of the report. The corresponding author had full access to all the data in the study, and final responsibility for the decision to submit for publication.